Recombinant Human CD20 GST (N-Term) Protein


SDS-Page: Recombinant Human MS4A1/CD20 Protein [H00000931-P01] - 12.5% SDS-PAGE Stained with Coomassie Blue.

Product Details

Reactivity HuSpecies Glossary
Applications WB, ELISA, PA, AP

Order Details

Recombinant Human CD20 GST (N-Term) Protein Summary

A recombinant protein with GST-tag at N-terminal corresponding to the amino acids 1-297 of Human MS4A1 full-length ORF

Source: Wheat Germ (in vitro)


in vitro wheat germ expression system
Details of Functionality
This protein was produced in an in vitro wheat germ expression system that should preserve correct conformational folding that is necessary for biological function. While it is possible that this protein could display some level of activity, the functionality of this protein has not been explicitly measured or validated.
Wheat germ
Protein/Peptide Type
Full Length Recombinant Protein
>80% by SDS-PAGE and Coomassie blue staining


  • Immunoaffinity Purification
  • Protein Array
  • Western Blot
Theoretical MW
58.41 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Read Publication using H00000931-P01.

Packaging, Storage & Formulations

Store at -80C. Avoid freeze-thaw cycles.
50 mM Tris-HCl, 10 mM reduced Glutathione, pH 8.0 in the elution buffer.
No Preservative
>80% by SDS-PAGE and Coomassie blue staining


This product is produced by and distributed for Abnova, a company based in Taiwan.

Alternate Names for Recombinant Human CD20 GST (N-Term) Protein

  • B1
  • B-lymphocyte antigen CD20
  • B-lymphocyte cell-surface antigen B1
  • B-lymphocyte surface antigen B1
  • Bp35
  • Bp35MGC3969
  • CD20 antigen
  • CD20 receptor
  • CD20
  • CD20S7
  • CVID5
  • LEU-16
  • Leukocyte surface antigen Leu-16
  • Ly-44
  • Membrane-spanning 4-domains subfamily A member 1
  • membrane-spanning 4-domains, subfamily A, member 1
  • MS4A1
  • MS4A2
  • S7


CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).


1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506.

2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426.

3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334.

4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181.

5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278.


This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: ICC/IF, IHC, IHC-P
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC/IF, In vitro, WB
Species: Hu
Applications: WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, IP, WB
Species: Ca, Hu, Pm, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, IHC, WB
Species: Hu, Mu, Rt
Applications: IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu
Applications: ICC/IF, WB
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), IHC, IP, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, Func, ICC/IF, IHC, IHC-Fr, IHC-P, IP, In vitro, In vivo, WB
Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu
Applications: CyTOF-ready, Flow, IMC, ICC/IF, IHC, IHC-P, WB
Species: Mu, Rt
Applications: Cell Depl, CyTOF-ready, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, InhibTFunc
Species: Hu
Applications: ICC/IF, IHC, IHC-P, KD, WB
Species: Hu
Applications: BA

Publications for CD20 Full Length Recombinant Protein (H00000931-P01)(1)

Reviews for CD20 Full Length Recombinant Protein (H00000931-P01) (0)

There are no reviews for CD20 Full Length Recombinant Protein (H00000931-P01). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

Video Protocols

WB Video Protocol

FAQs for CD20 Full Length Recombinant Protein (H00000931-P01). (Showing 1 - 4 of 4 FAQ).

  1. We are looking for human CD20 purified protein for use in ELISA. Can you estimate the level of purity for this protein? Cat # H000000931-P01. Also what is the difference between recombinant and partial recombinant H00000931-Q01-25ug.
    • The purity of H00000931-P01 is usually >80%. As for your 2nd question: the partial recombinant protein is made up of amino acids 210 - 297, with a GST-tag at the N-terminal. The full length recombinant protein is the entire protein with the GST-tag.
  2. I am developing mass spectrometry tools to study the interactions between antibodies and antigens and to accomplish epitope mapping. I currently have Rituximab antibody. Do you know if it will bind to your recombinant CD20 protein? Is this the best CD20 sample you have for such a study?
    • The CD20 protein you are referring to, H00000931-P01 is an Abnova protein, a Taiwanese company that we distribute for. This is a full length protein which does have a GST tag at the N-terminus and was expressed using the in vitro wheat germ expression system. This expression system allows for proper protein folding and activity however, does not glycosylate the proteins. Due to the fact that this protein was not used with the antibody you are referring to I cannot comment on the usage of these 2 products together. Our routine applications that we validate our products for includes Western blot, IHC, Immunofluorescence, IP, ELISA and flow. We cannot predict if this recombinant protein would work for your application.
  3. Have you tested binding activity of this protein to Rituximab ?
    • Our CD20 recombinant protein with catalogue number H00000931-P01 is produced by a Taiwanese company called Abnova, for whom we distribute. We do not perform any in-house testing or development of Abnova's products. Unless specifically stated, Abnova do not test the activity of their recombinant proteins. The proteins are produced in a cell-free wheat germ system and have an N-terminal 26kDa GST-tag. Due to the nature of the expression system, the proteins do not always undergo the same folding and post-translational modifications that they might undergo in an endogenous cell. We do not recommend this protein for use in functional assays and do not guarantee it for this use.
  4. As per the mentioned detail of CD20 recombinant protein (Cat No-#H00000931-P01), We need some check points. Does the product bind to Rituximab Antibody or it shows any activity in Surface plasmon resonance analysis?
    • The CD20 recombinant protein, H00000931-P01, is made by Abnova, a company based in Taiwan for whom we distribute. We only distribute this product and all testing information comes directly from Abnova. Unfortunately, I do not see that Abnova has tested this product with any Rituximab Antibody, so I do not have any information as to whether this protein binds. This protein is not active, and we can only guarantee this proteins's performance in the applications listed on the datasheet. Unfortunately, Abnova does not have any data on this protein's use in surface plasmon resonance. I apologize for any inconvenience.

Additional CD20 Products

Bioinformatics Tool for CD20 Full Length Recombinant Protein (H00000931-P01)

Discover related pathways, diseases and genes to CD20 Full Length Recombinant Protein (H00000931-P01). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for CD20 Full Length Recombinant Protein (H00000931-P01)

Discover more about diseases related to CD20 Full Length Recombinant Protein (H00000931-P01).

Pathways for CD20 Full Length Recombinant Protein (H00000931-P01)

View related products by pathway.

PTMs for CD20 Full Length Recombinant Protein (H00000931-P01)

Learn more about PTMs related to CD20 Full Length Recombinant Protein (H00000931-P01).

Research Areas for CD20 Full Length Recombinant Protein (H00000931-P01)

Find related products by research area.

Blogs on CD20.

Antigen-loss relapse after successful CAR-T therapy; What do we do now?
By Jacqueline Carrico, BS, MD Tumor cell mechanisms driving tolerance to CAR-T Despite very promising results of CAR-T therapy in acute lymphoblastic leukemia, B-ALL, antigen-loss relapse has arisen as a major chall...  Read full blog post.

CD20 (Cluster of differentiation 20, Membrane-spanning 4-domains subfamily A member 1 (MS4A1), CVID5, B-lymphocyte surface antigen B1)
CD20 is a human B-lymphocyte surface molecule that spans the membrane four times and is expressed on both normal and malignant cells. The CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-ly...  Read full blog post.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human CD20 GST (N-Term) Protein and receive a gift card or discount.


Gene Symbol MS4A1